Literature DB >> 21565214

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.

Sònia Tugues1, Sina Koch, Laura Gualandi, Xiujuan Li, Lena Claesson-Welsh.   

Abstract

Vascular endothelial growth factors (VEGFs) are critical regulators of vascular and lymphatic function during development, in health and in disease. There are five mammalian VEGF ligands and three VEGF receptor tyrosine kinases. In addition, several VEGF co-receptors that lack intrinsic catalytic activity, but that indirectly modulate the responsiveness to VEGF contribute to the final biological effect. This review describes the molecular features of VEGFs, VEGFRs and co-receptors with focus on their role in the treatment of cancer.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565214     DOI: 10.1016/j.mam.2011.04.004

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  79 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

3.  Computational model of VEGFR2 pathway to ERK activation and modulation through receptor trafficking.

Authors:  Wan Hua Tan; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cell Signal       Date:  2013-08-29       Impact factor: 4.315

Review 4.  Systems biology of the microvasculature.

Authors:  Lindsay E Clegg; Feilim Mac Gabhann
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

5.  Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth.

Authors:  Guillaume Collet; Nathalie Lamerant-Fayel; Magdalena Tertil; Bouchra El Hafny-Rahbi; Jacek Stepniewski; Alan Guichard; Alexandra Foucault-Collet; Krzysztof Klimkiewicz; Stéphane Petoud; Agata Matejuk; Catherine Grillon; Alicja Jozkowicz; Jozef Dulak; Claudine Kieda
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

6.  Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.

Authors:  Shannon M Gallagher-Colombo; Amanda L Maas; Min Yuan; Theresa M Busch
Journal:  Isr J Chem       Date:  2012-09-01       Impact factor: 3.333

7.  Airway basal cell vascular endothelial growth factor-mediated cross-talk regulates endothelial cell-dependent growth support of human airway basal cells.

Authors:  Giacomo Curradi; Matthew S Walters; Bi-Sen Ding; Shahin Rafii; Neil R Hackett; Ronald G Crystal
Journal:  Cell Mol Life Sci       Date:  2012-03-01       Impact factor: 9.261

8.  Epigenetic control of hypoxia inducible factor-1α-dependent expression of placental growth factor in hypoxic conditions.

Authors:  Laura Tudisco; Floriana Della Ragione; Valeria Tarallo; Ivana Apicella; Maurizio D'Esposito; Maria Rosaria Matarazzo; Sandro De Falco
Journal:  Epigenetics       Date:  2014-02-06       Impact factor: 4.528

9.  Targeting angiogenesis as a therapeutic means to reinforce osteocyte survival and prevent nonunions in the aftermath of radiotherapy.

Authors:  Alexis Donneys; Noah S Nelson; Erin E Page; Sagar S Deshpande; Peter A Felice; Catherine N Tchanque-Fossuo; Joshua P Spiegel; Steven R Buchman
Journal:  Head Neck       Date:  2014-07-10       Impact factor: 3.147

Review 10.  Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.

Authors:  Andrew G Winer; Robert J Motzer; A Ari Hakimi
Journal:  Urol Clin North Am       Date:  2015-10-31       Impact factor: 2.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.